TY - JOUR
T1 - Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post–Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction
T2 - An Advancing Liver Therapeutic Approaches Group Study
AU - Advancing Liver Therapeutic Approaches (ALTA) Study Group
AU - Ge, Jin
AU - Lai, Jennifer C.
AU - Boike, Justin Richard
AU - German, Margarita
AU - Jest, Nathaniel
AU - Morelli, Giuseppe
AU - Spengler, Erin
AU - Said, Adnan
AU - Lee, Alexander
AU - Hristov, Alexander
AU - Desai, Archita P.
AU - Junna, Shilpa
AU - Pokhrel, Bhupesh
AU - Couri, Thomas
AU - Paul, Sonali
AU - Frenette, Catherine
AU - Christian-Miller, Nathaniel
AU - Laurito, Marcela
AU - Verna, Elizabeth C.
AU - Rahim, Usman
AU - Goel, Aparna
AU - Das, Arighno
AU - Pine, Stewart
AU - Gregory, Dyanna
AU - VanWagner, Lisa B.
AU - Kolli, Kanti Pallav
N1 - Publisher Copyright:
Copyright © 2020 by the American Association for the Study of Liver Diseases.
PY - 2021/2
Y1 - 2021/2
N2 - Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for portal hypertensive complications, but its effect on renal function is not well characterized. Here we describe renal function and characteristics associated with renal dysfunction at 30 days post-TIPS. Adults with cirrhosis who underwent TIPS at 9 hospitals in the United States from 2010 to 2015 were included. We defined “post-TIPS renal dysfunction” as a change in estimated glomerular filtration rate (ΔeGFR) ≤−15 and eGFR ≤ 60 mL/min/1.73 m2 or new renal replacement therapy (RRT) at day 30. We identified the characteristics associated with post-TIPS renal dysfunction by logistic regression and evaluated survival using adjusted competing risk regressions. Of the 673 patients, the median age was 57 years, 38% of the patients were female, 26% had diabetes mellitus, and the median MELD-Na was 17. After 30 days post-TIPS, 66 (10%) had renal dysfunction, of which 23 (35%) required new RRT. Patients with post-TIPS renal dysfunction, compared with those with stable renal function, were more likely to have nonalcoholic fatty liver disease (NAFLD; 33% versus 17%; P = 0.01) and comorbid diabetes mellitus (42% versus 24%; P = 0.001). Multivariate logistic regressions showed NAFLD (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.00-4.17; P = 0.05), serum sodium (Na; OR, 1.06 per mEq/L; 95% CI, 1.01-1.12; P = 0.03), and diabetes mellitus (OR, 2.04; 95% CI, 1.16-3.61; P = 0.01) were associated with post-TIPS renal dysfunction. Competing risk regressions showed that those with post-TIPS renal dysfunction were at a higher subhazard of death (subhazard ratio, 1.74; 95% CI, 1.18-2.56; P = 0.01). In this large, multicenter cohort, we found NAFLD, diabetes mellitus, and baseline Na associated with post-TIPS renal dysfunction. This study suggests that patients with NAFLD and diabetes mellitus undergoing TIPS evaluation may require additional attention to cardiac and renal comorbidities before proceeding with the procedure.
AB - Transjugular intrahepatic portosystemic shunt (TIPS) is an effective intervention for portal hypertensive complications, but its effect on renal function is not well characterized. Here we describe renal function and characteristics associated with renal dysfunction at 30 days post-TIPS. Adults with cirrhosis who underwent TIPS at 9 hospitals in the United States from 2010 to 2015 were included. We defined “post-TIPS renal dysfunction” as a change in estimated glomerular filtration rate (ΔeGFR) ≤−15 and eGFR ≤ 60 mL/min/1.73 m2 or new renal replacement therapy (RRT) at day 30. We identified the characteristics associated with post-TIPS renal dysfunction by logistic regression and evaluated survival using adjusted competing risk regressions. Of the 673 patients, the median age was 57 years, 38% of the patients were female, 26% had diabetes mellitus, and the median MELD-Na was 17. After 30 days post-TIPS, 66 (10%) had renal dysfunction, of which 23 (35%) required new RRT. Patients with post-TIPS renal dysfunction, compared with those with stable renal function, were more likely to have nonalcoholic fatty liver disease (NAFLD; 33% versus 17%; P = 0.01) and comorbid diabetes mellitus (42% versus 24%; P = 0.001). Multivariate logistic regressions showed NAFLD (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.00-4.17; P = 0.05), serum sodium (Na; OR, 1.06 per mEq/L; 95% CI, 1.01-1.12; P = 0.03), and diabetes mellitus (OR, 2.04; 95% CI, 1.16-3.61; P = 0.01) were associated with post-TIPS renal dysfunction. Competing risk regressions showed that those with post-TIPS renal dysfunction were at a higher subhazard of death (subhazard ratio, 1.74; 95% CI, 1.18-2.56; P = 0.01). In this large, multicenter cohort, we found NAFLD, diabetes mellitus, and baseline Na associated with post-TIPS renal dysfunction. This study suggests that patients with NAFLD and diabetes mellitus undergoing TIPS evaluation may require additional attention to cardiac and renal comorbidities before proceeding with the procedure.
UR - http://www.scopus.com/inward/record.url?scp=85099044319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099044319&partnerID=8YFLogxK
U2 - 10.1002/lt.25949
DO - 10.1002/lt.25949
M3 - Article
C2 - 33217178
AN - SCOPUS:85099044319
SN - 1527-6465
VL - 27
SP - 329
EP - 340
JO - Liver Transplantation
JF - Liver Transplantation
IS - 3
ER -